Nav: Home

Precision-medicine platform for mild Alzheimer's disease and at-risk individuals

November 13, 2018

Alzheimer's disease (AD) is a progressive, neurodegenerative condition in which individuals exhibit memory loss, dementia, and impaired metabolism. Nearly all previous single-domain studies to treat AD have failed, likely because it is a complex disease with multiple underlying drivers contributing to risk, onset, and progression. Keine et al. explored the efficacy of a multidomain therapy approach based on the disease risk factor status specific to individuals with AD diagnosis or concern. Their findings indicate previously unidentified connectivity between AD risk factors, suggesting that treatment regimens should be tailored to the individual, and should be multi-modal to simultaneously return risk factors to a normative state. If successfully performed, the possibility to slow progression of AD and even reverse aspects of cognitive decline may become achievable.

Keine et al. completed analysis for forty subjects with subjective cognitive decline (SCD) and mild cognitive impairment (MCI), using novel software from uMETHOD Health. The software is designed to execute a precision-medicine-based approach to develop personalized treatment recommendations, with the goal of slowing or reversing biologic drivers of AD. AD-associated inputs encompassed genomic data, biospecimen measurements, imaging data (such as MRIs or PET scans), medical histories, medications, allergies, comorbidities, relevant lifestyle factors, and results of neuropsychology testing. Algorithms were employed to prioritize physiologic and lifestyle states with the highest probability of contributing to disease status, and these priorities were incorporated into a personalized care plan, which was delivered to physicians and supported by health coaches to increase adherence. With an average of 8.4 months on their treatment plans (equal to about 2.8 iterations of care plans), 80% of individuals in the study showed overall improved memory function scores or held steady, as measured by cognitive evaluations.

It is increasingly recognized that early intervention is key to developing an effective therapy for AD; a precision-medicine platform enables an actionable multidomain therapy for those in the early stages of the disease. Many of the underlying pathologic drivers of the disease (e.g., high homocysteine, genetic biases, insulin resistance, poor diet, poor sleep, lack of exercise, chronic inflammation, toxicity) are modifiable, allowing persons to reduce their risk and potentially delay disease onset. With a multitude of underlying drivers of AD, genetic factors, comorbidities, medications, and optimizations for each person, the amount of data used in generating a care plan quickly accumulates, making a timely process beyond the scope of what a physician can do by hand, and do well quickly. But where manual methods fail, clinical informatics platforms excel. These platforms can provide a personalized treatment method for each individual in a repeatable, predictable, and timely manner. Applying these complex treatment plans to a broader audience through the development of other disease state-specific algorithms could increase the quality of life for many in the aging population.
-end-
Access the article here: http://www.eurekaselect.com/166449

Media Contact:

Helen Bertelli
helen@benecomms.io">helen@benecomms.io

Reference: Keine, Dorothy, et al. Development, application, and results from a precision-medicine platform that personalizes multi-modal treatment plans for mild Alzheimer's disease and at-risk individuals. Current Aging Science, 2018, DOI: 10.2174/1874609811666181019101430

Bentham Science Publishers

Related Cognitive Decline Articles:

High blood pressure treatment may slow cognitive decline
Among middle-aged and older adults, high blood pressure accelerated cognitive decline and treatment slowed the regression.
Depression symptoms in Alzheimer's could be signs for cognitive decline
Depression symptoms in cognitively healthy older individuals together with brain amyloid, a biological marker of Alzheimer's could trigger changes in memory and thinking over time.
Model predicts cognitive decline due to Alzheimer's, up to two years out
An artificial intelligence model developed at MIT predicts cognitive decline of patients at risk for Alzheimer's disease by predicting their cognition test scores up to 2 years in the future.
Cognitive decline may accelerate after heart attack, angina
Adults with incident coronary heart disease (CHD) are at higher risk for faster cognitive decline in the long-term, according to a study published today in the Journal of the American College of Cardiology.
Healthy blood vessels may delay cognitive decline
High blood pressure may affect conditions such as Alzheimer's disease by interfering with the brain's waste management system, according to new research in rats published in JNeurosci.
More Cognitive Decline News and Cognitive Decline Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...